The United States has legitimate reasons to be concerned about China's rapid ascent in clinical research. Federal officials note that China now conducts more clinical drug trials than the US, and by one estimate, it accounted for 39% of all global trials in 2024. However, framing the response as a simple race risks missing the larger objective: building a faster, safer, and more trusted system for developing medicines that the world can rely on.
The Food and Drug Administration's (FDA) new pilot program, part of a broader Department of Health and Human Services initiative, aims to accelerate early-stage trials and could shorten development timelines by six to 12 months. This responds to a real shift: more early drug research has moved overseas—to China, but also to countries like Australia—where companies cite lower costs, faster regulatory processes, tax incentives, and more efficient clinical networks.
Why Early-Stage Trials Matter
Early-stage trials are not just technical exercises; they are the front door of biomedical innovation. Where they take place shapes which patients gain early access to new therapies, which institutions build expertise, where investment flows, and whose regulatory standards become the global norm. This has direct implications for Asia, where countries like Japan, South Korea, and Singapore are also investing heavily in clinical research infrastructure.
The numbers behind America's anxiety are striking. China's dominance in trial volume is partly driven by its large patient population and streamlined regulatory environment. But the quality and trustworthiness of those trials remain a concern for international regulators and pharmaceutical companies.
Still, the right question is not whether America can “beat” China. It is whether the US can make its system fast enough to attract science, rigorous enough to protect patients, and open enough to produce evidence the world can trust. The proposed reforms point in that direction.
The FDA plans to give companies earlier clarity on manufacturing requirements, dose selection, and approval pathways, and to review some applications on a rolling basis before all documents are complete. The agency has also reaffirmed that, in certain cases, a single high-quality late-stage trial backed by confirmatory evidence can support approval, instead of the two trials long expected.
These changes could help the US retain its edge in drug development, but they also raise questions about how other countries in the Indo-Pacific are positioning themselves. For instance, China's role in building Indonesia's nickel boom highlights how Beijing uses strategic investments to gain influence in critical sectors. Similarly, the US must consider how its regulatory framework affects partnerships with Asian nations.
Trust is not just a soft factor; it is a competitive advantage. If the US can demonstrate that its clinical trials produce reliable, ethically conducted results, it will attract global investment and talent. This is especially important as quantum firms sidestep US-China rivalry and as Asia's space race intensifies.
The FDA's pilot program is a step in the right direction, but it must be part of a broader strategy that prioritizes quality over speed. The US cannot afford to sacrifice rigor for the sake of winning a race. Instead, it should aim to set the global standard for clinical research—one that other countries, including those in Asia, will want to follow.
